General Information:

Id: 3,922
Diseases: Diabetes mellitus, type II - [OMIM]
Insulin resistance
Homo sapiens
BTO:0000093 MCF-7 cell
article
Reference: Duncan RE et al.(2005) Regulation of HMG-CoA reductase in MCF-7 cells by genistein, EPA, and DHA, alone and in combination with mevastatin Cancer Lett. 224: 221-228 [PMID: 15914273]

Interaction Information:

Comment Treatment with the isoflavone genistein or the long chain n-3 PUFAs DHA or EPA significantly inhibits the proliferation of MCF-7 human breast cancer cells in a concentration-dependent manner. Under the same treatment conditions, genistein, EPA and DHA also down-regulated MCF-7 cell HMG-CoA reductase as measured by the enzyme activity of cell-free supernatants. A dose-dependent response was seen for genistein on HMG-CoA reductase activity.
Formal Description
Interaction-ID: 39809

drug/chemical compound

Genistein

decreases_activity of

in MCF-7 breast cancer cells
Drugbank entries Show/Hide entries for Genistein
Comment Treatment with the isoflavone genistein or the long chain n-3 PUFAs DHA or EPA significantly inhibits the proliferation of MCF-7 human breast cancer cells in a concentration-dependent manner. Under the same treatment conditions, genistein, EPA and DHA also down-regulated MCF-7 cell HMG-CoA reductase as measured by the enzyme activity of cell-free supernatants. A dose-dependent response was seen for genistein on HMG-CoA reductase activity.
Formal Description
Interaction-ID: 39810

drug/chemical compound

Docosahexaenoic acid

decreases_activity of

in MCF-7 breast cancer cells
Comment Treatment with the isoflavone genistein or the long chain n-3 PUFAs DHA or EPA significantly inhibits the proliferation of MCF-7 human breast cancer cells in a concentration-dependent manner. Under the same treatment conditions, genistein, EPA and DHA also down-regulated MCF-7 cell HMG-CoA reductase as measured by the enzyme activity of cell-free supernatants. A dose-dependent response was seen for genistein on HMG-CoA reductase activity.
Formal Description
Interaction-ID: 39823

drug/chemical compound

Eicosapentaenoic acid

decreases_activity of

in MCF-7 breast cancer cells
Comment Treatment with the isoflavone genistein or the long chain n-3 PUFAs DHA or EPA significantly inhibits the proliferation of MCF-7 human breast cancer cells in a concentration-dependent manner. Under the same treatment conditions, genistein, EPA and DHA also down-regulated MCF-7 cell HMG-CoA reductase as measured by the enzyme activity of cell-free supernatants. A dose-dependent response was seen for genistein on HMG-CoA reductase activity.
Formal Description
Interaction-ID: 39824

drug/chemical compound

Genistein

decreases_activity of

gene/protein

HMGCR

in MCF-7 breast cancer cells
Drugbank entries Show/Hide entries for Genistein or HMGCR
Comment Treatment with the isoflavone genistein or the long chain n-3 PUFAs DHA or EPA significantly inhibits the proliferation of MCF-7 human breast cancer cells in a concentration-dependent manner. Under the same treatment conditions, genistein, EPA and DHA also down-regulated MCF-7 cell HMG-CoA reductase as measured by the enzyme activity of cell-free supernatants. A dose-dependent response was seen for genistein on HMG-CoA reductase activity.
Formal Description
Interaction-ID: 39825

drug/chemical compound

Eicosapentaenoic acid

decreases_activity of

gene/protein

HMGCR

in MCF-7 breast cancer cells
Drugbank entries Show/Hide entries for HMGCR
Comment Treatment with the isoflavone genistein or the long chain n-3 PUFAs DHA or EPA significantly inhibits the proliferation of MCF-7 human breast cancer cells in a concentration-dependent manner. Under the same treatment conditions, genistein, EPA and DHA also down-regulated MCF-7 cell HMG-CoA reductase as measured by the enzyme activity of cell-free supernatants. A dose-dependent response was seen for genistein on HMG-CoA reductase activity.
Formal Description
Interaction-ID: 39826

drug/chemical compound

Docosahexaenoic acid

decreases_activity of

gene/protein

HMGCR

in MCF-7 breast cancer cells
Drugbank entries Show/Hide entries for HMGCR
Comment Treatment of MCF-7 cells with mevastatin alone resulted in a 10- to 15-fold induction of HMG-CoA reductase activity in association with a 2.5- to 3.5-fold induction of HMG-CoA reductase mRNA expression. Genistein significantly abrogated the induction of reductase, the activity of which was 40% lower in cells treated concomitantly with genistein and mevastatin compared to cells treated with mevastatin alone. Reductase mRNA, measured by real-time PCR, was unchanged by genistein in mevastatin-treated cells. This indicates that down-regulation of reductase activity by genistein in these cells was mediated entirely through post-transcriptional events.
Formal Description
Interaction-ID: 39827

drug/chemical compound

Mevastatin

increases_activity of

gene/protein

HMGCR

in MCF-7 breast cancer cells
Drugbank entries Show/Hide entries for Mevastatin or HMGCR
Comment Treatment of MCF-7 cells with mevastatin alone resulted in a 10- to 15-fold induction of HMG-CoA reductase activity in association with a 2.5- to 3.5-fold induction of HMG-CoA reductase mRNA expression. Genistein significantly abrogated the induction of reductase, the activity of which was 40% lower in cells treated concomitantly with genistein and mevastatin compared to cells treated with mevastatin alone. Reductase mRNA, measured by real-time PCR, was unchanged by genistein in mevastatin-treated cells. This indicates that down-regulation of reductase activity by genistein in these cells was mediated entirely through post-transcriptional events.
Formal Description
Interaction-ID: 39828

drug/chemical compound

Mevastatin

increases_expression of

gene/protein

HMGCR

in MCF-7 breast cancer cells
Drugbank entries Show/Hide entries for Mevastatin or HMGCR
Comment Treatment of MCF-7 cells with mevastatin alone resulted in a 10- to 15-fold induction of HMG-CoA reductase activity in association with a 2.5- to 3.5-fold induction of HMG-CoA reductase mRNA expression. Genistein significantly abrogated the induction of reductase, the activity of which was 40% lower in cells treated concomitantly with genistein and mevastatin compared to cells treated with mevastatin alone. Reductase mRNA, measured by real-time PCR, was unchanged by genistein in mevastatin-treated cells. This indicates that down-regulation of reductase activity by genistein in these cells was mediated entirely through post-transcriptional events.
Formal Description
Interaction-ID: 39829

drug/chemical compound

Genistein

decreases_activity of

drug/chemical compound

Mevastatin

in MCF-7 breast cancer cells
Drugbank entries Show/Hide entries for Genistein or Mevastatin
Comment Treatment of MCF-7 cells with mevastatin alone resulted in a 10- to 15-fold induction of HMG-CoA reductase activity in association with a 2.5- to 3.5-fold induction of HMG-CoA reductase mRNA expression. Genistein significantly abrogated the induction of reductase, the activity of which was 40% lower in cells treated concomitantly with genistein and mevastatin compared to cells treated with mevastatin alone. Reductase mRNA, measured by real-time PCR, was unchanged by genistein in mevastatin-treated cells. This indicates that down-regulation of reductase activity by genistein in these cells was mediated entirely through post-transcriptional events.
Formal Description
Interaction-ID: 39830

drug/chemical compound

Genistein

NOT affects_expression of

gene/protein

HMGCR

in MCF-7 breast cancer cells
Drugbank entries Show/Hide entries for Genistein or HMGCR
Comment DHA also significantly attenuated the induction of HMG-CoA reductase activity by mevastatin in MCF-7 cells. Reductase activity was 15% lower in cells treated concomitantly with DHA and mevastatin, compared to cells treated with mevastatin alone. The magnitude of this down-regulation, however, was smaller than that observed in cells grown in the absence of mevastatin, in which DHA produced an 30% reduction in HMG-CoA reductase activity. DHA caused no change in reductase mRNA in mevastatin-treated cells, indicating that regulation of reductase activity by DHA was mediated entirely at a post-transcriptional level. Unlike DHA or genistein, EPA produced no change in HMG-CoA reductase in mevastatin-treated cells.
Formal Description
Interaction-ID: 39831

drug/chemical compound

Docosahexaenoic acid

decreases_activity of

drug/chemical compound

Mevastatin

in MCF-7 breast cancer cells
Drugbank entries Show/Hide entries for
Comment DHA also significantly attenuated the induction of HMG-CoA reductase activity by mevastatin in MCF-7 cells. Reductase activity was 15% lower in cells treated concomitantly with DHA and mevastatin, compared to cells treated with mevastatin alone. The magnitude of this down-regulation, however, was smaller than that observed in cells grown in the absence of mevastatin, in which DHA produced an 30% reduction in HMG-CoA reductase activity. DHA caused no change in reductase mRNA in mevastatin-treated cells, indicating that regulation of reductase activity by DHA was mediated entirely at a post-transcriptional level. Unlike DHA or genistein, EPA produced no change in HMG-CoA reductase in mevastatin-treated cells.
Formal Description
Interaction-ID: 39832

drug/chemical compound

Docosahexaenoic acid

NOT affects_expression of

gene/protein

HMGCR

in MCF-7 breast cancer cells
Drugbank entries Show/Hide entries for HMGCR
Comment DHA also significantly attenuated the induction of HMG-CoA reductase activity by mevastatin in MCF-7 cells. Reductase activity was 15% lower in cells treated concomitantly with DHA and mevastatin, compared to cells treated with mevastatin alone. The magnitude of this down-regulation, however, was smaller than that observed in cells grown in the absence of mevastatin, in which DHA produced an 30% reduction in HMG-CoA reductase activity. DHA caused no change in reductase mRNA in mevastatin-treated cells, indicating that regulation of reductase activity by DHA was mediated entirely at a post-transcriptional level. Unlike DHA or genistein, EPA produced no change in HMG-CoA reductase in mevastatin-treated cells.
Formal Description
Interaction-ID: 39833

drug/chemical compound

Eicosapentaenoic acid

NOT decreases_activity of

drug/chemical compound

Mevastatin

in MCF-7 breast cancer cells
Drugbank entries Show/Hide entries for